RD Saúde (B3: RADL3) stock: the official figures
RD Saúde (Raia Drogasil S.A.) is listed on B3, the São Paulo stock exchange, under the ticker RADL3. In fiscal 2025 it reported revenue of BRL 44,250m and a net profit of BRL 1,297m, according to the annual accounts it filed with the regulator.
Identifiers for RD Saúde: CNPJ 61.585.865/0001-51.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | BRL 44,250m | BRL 38,872m | +13.8% |
| Operating profit | BRL 2,744m | BRL 2,352m | +16.6% |
| Net profit | BRL 1,297m | BRL 1,200m | +8.1% |
| Operating margin | 6.2% | 6.1% | +0.1 pts |
| Net margin | 2.9% | 3.1% | −0.2 pts |
| Total assets | BRL 25,170m | BRL 22,164m | +13.6% |
| Equity | BRL 7,322m | BRL 6,433m | +13.8% |
| Cash | BRL 509.6m | BRL 528.0m | −3.5% |
| Operating cash flow | BRL 2,431m | BRL 2,771m | −12.3% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
10 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Document |
|---|---|---|---|---|
| 2025 | BRL 44,250m | BRL 2,744m | BRL 1,297m | Annual report |
| 2024 | BRL 38,872m | BRL 2,352m | BRL 1,200m | Annual report |
| 2023 | BRL 33,974m | BRL 2,080m | BRL 1,055m | Annual report |
| 2022 | BRL 29,067m | BRL 1,839m | BRL 996.1m | Annual report |
| 2021 | BRL 24,127m | BRL 1,366m | BRL 751.9m | Annual report |
| 2020 | BRL 20,067m | BRL 916.0m | BRL 484.4m | Annual report |
| 2019 | BRL 17,566m | BRL 1,118m | BRL 772.2m | Annual report |
| 2018 | BRL 14,801m | BRL 721.5m | BRL 502.4m | Annual report |
| 2017 | BRL 13,213m | BRL 792.6m | BRL 511.2m | Annual report |
| 2016 | BRL 11,257m | BRL 705.5m | BRL 447.7m | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of RD Saúde. Year by year: revenue, net income and dividends paid.
Dividends
In fiscal 2025, RD Saúde paid BRL 652.8m in dividends, 50.3% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2025 | BRL 652.8m | 50.3% |
| 2024 | BRL 474.6m | 39.6% |
| 2023 | BRL 465.9m | 44.2% |
| 2022 | BRL 324.1m | 32.5% |
| 2021 | BRL 265.0m | 35.2% |
| 2020 | BRL 190.5m | 39.3% |
| 2019 | BRL 186.6m | 24.2% |
| 2018 | BRL 173.6m | 34.6% |
| 2017 | BRL 170.8m | 33.4% |
| 2016 | BRL 153.3m | 34.3% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Frequently asked questions about RD Saúde
- How much did RD Saúde earn in fiscal 2025?
- RD Saúde reported a net profit of BRL 1,297m for fiscal 2025, on revenue of BRL 44,250m. The year before it reported a net profit of BRL 1,200m.
- Does RD Saúde pay a dividend?
- In fiscal 2025, RD Saúde paid BRL 652.8m in dividends, 50.3% of its net profit, according to its cash flow statement.
- Where is RD Saúde listed?
- RD Saúde is listed on B3, the São Paulo stock exchange, under the ticker RADL3.
- Where do the figures for RD Saúde come from?
- From the annual financial statements (DFP) that RD Saúde files with the CVM, the Brazilian securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual financial statements (DFP) that RD Saúde files with the CVM, the Brazilian securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.